Skip to NavigationSkip to content

Idorsia reveals it is working with Neurocrine on new epilepsy drug deal

Published on 10/01/20 at 10:11am

Idorsia revealed its 2019 deal for its investigational epilepsy medicine was with Neurocrine Biosciences, and it is potentially worth more than $400 million.

The agreement calls for Idorsia to get $365 million in development, $45 million in cash and $7 million in research. It will also get regulatory milestone payments if Neurocrine exercises its option within 30 days of the FDA accepting an investigational new drug application, which is expected for mid-2020. There would also be royalties for its epilepsy drug, known as ACT-709478.

The drug is designed to target calcium channels throughout the central nervous system believed to play a role in epilepsy. It has completed an early safety study in healthy adults, and is slated to start a Phase 2 trial in rare paediatric epilepsy this year.

Kevin Gorman, Neurocrine CEO, said: “We are excited to leverage the scientific expertise of Idorsia in T-type calcium channel inhibition to potentially advance a Phase 2 ready compound to help people suffering from epilepsy.”

In 2019, Idorsia got a $5 million payment for a licensing option for ACT-709478, but they did not reveal Neurocrine’s identity.

Conor Kavanagh

 

Mission Statement
Pharmafile.com is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for Pharmafile.com and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches